Iambic Therapeutics has unveiled Enchant, an innovative AI-powered platform aimed at transforming the earliest stages of drug discovery. Enchant, a sophisticated multi-modal transformer model, is designed to predict clinical properties of new drug candidates, helping scientists assess a drug’s viability long before clinical trials begin. The platform’s predictive capabilities could lower development costs and reduce risks associated with clinical trials by filtering out less promising drug candidates early in the process.
The Enchant platform enables researchers to analyse a drug’s pharmacokinetics, understanding how a drug will interact within the human body. This approach provides insights on potential drug behaviour, allowing teams to make informed decisions on which candidates to pursue further. “Enchant represents a new frontier in AI-driven drug discovery,” says MIT Associate Professor Connor Coley. “By leveraging Enchant’s predictive capabilities, developers can accelerate the process of designing, making, and testing drug candidates, ultimately reducing the burden of traditional experimentation methods.”
The AI model, trained on a blend of preclinical and limited clinical data, uses data from multiple sources to predict key drug properties influencing clinical outcomes. Enchant is capable of integrating diverse data types generated at different research stages, addressing challenges in data variability and quality. According to Fred Manby, Chief Technology Officer at Iambic, Enchant’s predictions have already outperformed existing models in clinical outcome accuracy.
Iambic’s latest tool is poised to enhance the efficiency of drug discovery, bringing the field closer to safer, more cost-effective therapeutic development.
